Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 921-931

  Kobayashi, Makiko ^a   Takahashi Suzuki, Ikuko ^a   Shimomura, Toshiyasu ^a   Iwasawa, Yoshikazu ^a   Hirai, Hiroshi ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cdk; Cell death by Cdk inhibitor; Hematological toxicity; Lymphocyte; Pan Cdk inhibitor; Small molecule inhibitor

Indexed keywords

CAMPTOTHECIN; CARBOXY TERMINAL TELOPEPTIDE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 6 INHIBITOR; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PAN CYCLIN DEPENDENT KINASE INHIBITOR; RNA POLYMERASE II; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL; CANCER CELL; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETERMINATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCUBATION TIME; LEUKEMIA CELL; LEUKOCYTE; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; ANIMAL; CELL STRAIN HEK293; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSCRIPTION; IC 50; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; RAT; SIGNAL TRANSDUCTION; TIME;

ANIMALS; CELL DEATH; CYCLIN-DEPENDENT KINASES; HEK293 CELLS; HUMANS; IMMUNOSUPPRESSION; INHIBITORY CONCENTRATION 50; LEUKOCYTES; LYMPHOCYTES; MICE; MICE, INBRED ICR; NF-KAPPA B; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RATS; RNA POLYMERASE II; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 84856068286     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9448-9     Document Type: Article

References (42)

1. Sherr CJ (1996) Cancer cell cycles. Science 274:1672-1677
2. Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revised. Cancer Res 60:3689-3695
3. van den Heuvel S, Harlow E (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262:2050-2054
4. Dyson N (1998) The regulation of E2F by pRb-family proteins. Genes Dev 12:2245-2262
5. Carnero A (2002) Targeting the cell cycle for cancer therapy. Br J Cancer 87:129-133
6. Elsayed YA, Sausville EA (2001) Selected novel anticancer treatments targeting cell signaling proteins. Oncologist 6:517-537
7. Falco GD, Giordan A (1998) CDK9 (PITALRE): a multifunctional cdc2-related kinase. J Cell Physiol 177:501-506
8. Palancade B, Bensaude O (2003) Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem 270:3859-3870
9. Price DH (2000) P-TEFb a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 20:2629-2634
10. Dhavan R, Tsai L-H (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2:749-759
11. Lilja L, Yang S, Webb D, Juntti-Berggren L, Berggren P, Bark C (2001) Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 276:34199-34205
12. Hirai H, Kawanishi N, Iwasawa Y (2009) Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Front Med Chem 4:347-370
13. Dickson MA, Schwartz GK (2009) Development of cell-cycle inhibitors for cancer therapy. Current Oncol 16:36-43
14. Malumbres M, Pevarello P, Barbacid M, Bischoff JR (2007) CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 29:16-21
15. Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM (2002) Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasm. J Clin Oncol 20:4074-4082
16. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF, Koss JW, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosup-pression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91:2482-2490
17. Hirai H, Takahashi-Suzuki I, Shimomura T, Fukasawa K, Machida T, Takaki T, Kobayashi M, Eguchi T, Oki H, Arai T, Ichikawa K, Hasako S, Kodera T, Kawanishi N, Nakatsuru Y, Kotani H, Iwasawa Y (in press) Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest New Drugs. doi:10.1007/s10637-009-93848
18. Kawanishi N, Sugimoto T, Shibata J, Nakamura K, Masutani K, Ikuta M, Hirai H (2006) Structure-based drug design of a highly potent CDK1, 2, 4, 6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg Med Chem Lett 16:5122-5126
19. Shimamura T, Shibata J, Kurihara H, Mita T, Otsuki S, Sagara T, Hirai H, Iwasawa Y (2006) Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9. Bioorg Med Chem Lett 16:3751-4
20. Hirai H, Shimomura T, Kobayashi M, Eguchi T, Taniguchi E, Fukasawa K, Machida T, Oki H, Arai T, Ichikawa K, Hasako S, Haze K, Kodera T, Kawanishi N, Takahashi-Suzuki, I, Nakatsuru Y, Kotani H, Iwasawa Y (2010) Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo. Cell Cycle 9:1590-1600
21. Chen PL, Scully P, Shew JY, Wang JYJ, Lee WH (1989) Phosphorylation of the retinoblastoma gene products is modulated during the cell cycle and cellular differentiation. Cell 58:1193-1198
22. Furukawa Y, DeCaprio JA, Freedman A, Kanakura Y, Nakamura M, Ernst TJ, Livingston DM, Griffin JD (1990) Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci USA 87:2770-2774
23. Terada N, Lucas JJ, Gelfand EW (1991) Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53. J Immunol 147:698-704
24. Modiano JF, Domenico J, Szepesi A, Lucas JJ, Gelfand EW (1994) Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. J Biol Chem 269:32972-32978
25. Nagasawa M, Melamed I, Kupfer A, Gelfand EW, Lucas JJ (1997) Rapid nuclear translocation and increased activity of cyclin-dependent kinase 6 after Tcell activation. J Immunol 158:5146-5154
26. te Poele RH, Okorokov AL, Joel SP (1999) RNA synthesis block by 5, 6-dichloro-1-ß-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene 18:5765-5772
27. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM (2001) NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 8:327-337
28. Luecke HF, Yamamoto KR (2005) The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev 19:1116-1127
29. Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol; mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513-2519
30. Hahntow I, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, Peschel C, Decker T (2004) Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18:747-755
31. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W (2009) Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113:4637-4645
32. MacCallum DE, Melville J, Frame S, Watt K, Anderson S (2005) Gianella-Borradori A, Lane DP, Green SR. Seliciclib (CYC202, R-Roscivitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399-5407
33. Cai D, Latham VMJ, Zhang X, Shapiro GI (2006) Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 66:9270-9280
34. Francois S, El Benna J, Dang PM, Pedruzzi E, Gougerot-Pocidalo MA, Elbim C (2005) Inhibition of neutrophil apoptosis by TLR agonists in whole blood; involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol 174:3633-3642
35. Patke A, Mecklenbrauker I, Tarakhovsky A (2004) Survival signaling in resting B cells. Curr Opin Immunol 16:251-255
36. Siebenlist U, Brown K, Claudio E (2005) Control of lymphocyte development by nuclear factor-kappaB. Nature Rev Immunol 5:435-445
37. Kim DM, Koo SY, Jeon K, Kim MH, Lee J, Hong CY, Jeong SW (2003) Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 63:621-626
38. Takada Y, Aggarwal BB (2004) Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279:4750-4759
39. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2:1-11
40. Chao SH, Price DH (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276:31793-31799
41. Lu X, Burgan WE, Cerra MA, Chuang EY, Tsai MH, Tofilon PJ, Camphausen K (2004) Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther 3:861-872
42. Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Gimenez MS, Dent P, Grant S (2007) Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther 6:692-702